- Therapeutic Cataract & Refractive
- Lens Technology
- Glasses
- Ptosis
- Comprehensive Eye Exams
- AMD
- COVID-19
- DME
- Ocular Surface Disease
- Optic Relief
- Geographic Atrophy
- Cornea
- Conjunctivitis
- LASIK
- Myopia
- Presbyopia
- Allergy
- Nutrition
- Pediatrics
- Retina
- Cataract
- Contact Lenses
- Lid and Lash
- Dry Eye
- Glaucoma
- Refractive Surgery
- Comanagement
- Blepharitis
- OCT
- Patient Care
- Diabetic Eye Disease
- Technology
Ophthalmic solution development candidate in phase 1 trial
Lux Biosciences began a phase 1 study of LX214, a proprietary topical ophthalmic solution containing the next-generation calcineurin inhibitor voclosporin.
Key Points
Jersey City, NJ-Lux Biosciences began a phase 1 study of LX214, a proprietary topical ophthalmic solution containing the next-generation calcineurin inhibitor voclosporin. The company says it is developing LX214 as a potential treatment for keratoconjunctivitis sicca and other chronic inflammatory ocular surface diseases.
"We are pleased with the progress of our program for LX214, which we advanced from inception into the clinic in 18 months, in parallel with our LX211 and LX201 phase 3 development programs," said Ulrich Grau, PhD, Lux Biosciences president and chief executive officer.
The preclinical data indicated that LX214 has higher drug levels of a calcineurin inhibitor in target tissues in the eye compared with other dry eye therapies, does not cause ocular irritation, and the 24-hour therapeutic drug levels in the eye provide a rationale for daily dosing.
